Verrica to present VP-315 basal cell carcinoma data at dermatology meeting
Tweet Send to a Friend
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) will present Phase 2 clinical data for its VP-315 treatment at the 2026 Society for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
